Global Study Tracks Adoption Rates of Long-Acting Antipsychotics in Schizophrenia Care
A meta-analysis involving more than 1.6 million participants found that 18.7 percent of individuals with schizophrenia receive long-acting injectable antipsychotics. Prescribing rates varied significantly by region, led by Europe at 26.0 percent compared to lower adoption in North America and Asia.
Key points
- A global review of over 1.6 million participants found an overall long-acting injectable antipsychotic utilization rate of 18.7 percent.
- Adoption rates varied significantly by region, reaching 26.0 percent in Europe, 15.7 percent in North America, and 14.3 percent in Asia.
- Researchers stressed that the pooled percentage reflects real-world practice differences rather than a universal standard of care.
Approximately 18.7 percent of individuals with schizophrenia receive long-acting injectable antipsychotics worldwide, according to a systematic review led by researchers Xiaobao Chen and Yubin Chen of Huzhou Normal University. The synthesis evaluated real-world prescription patterns across 26 observational studies encompassing 1,619,602 total participants and 258,382 users of long-acting injectables.
Geographic Differences in Clinical Practice
The analysis revealed notable differences in how these maintenance medications are prescribed across different regions. Clinical settings in Europe demonstrated the highest utilization rate at 26.0 percent. In comparison, prescription rates reached 15.7 percent in North America and 14.3 percent in Asia.
What to know: Long-acting injectable therapies are designed to assist with long-term treatment consistency in schizophrenia management. However, the researchers emphasized that the overall 18.7 percent pooled average reflects variations between healthcare settings rather than a established clinical target. Because the review evaluated observational data with high statistical heterogeneity, readers should view these findings as background trends and consult medical professionals for individualized treatment decisions.
Source Nature Health Sciences — nature.com/articles/s41398-026-04571-9 ↗
Read next
🏥Public HealthPreventive Services Task Force Resumes Meetings Under New Leadership
The U.S. Preventive Services Task Force is set to reconvene this week for the first time in over a year following a significant membership overhaul by Health Secretary Ro…
❤️Conditions & CareBlood-Based Genetic Signature May Predict CAR T-Cell Therapy Success in Lymphoma
Researchers have identified a specific RNA signature in blood plasma that may help predict how well lymphoma patients respond to CAR T-cell therapy.
🧠AI AnalysisUltraprocessed Diets May Impact Brain Reward Systems in Younger Adults
A Virginia Tech study suggests that individuals aged 18 to 21 may experience changes in brain reward processing after consuming ultraprocessed foods, a response not obser…
❤️Conditions & CareMigraine and Smoking Linked to Increased Early Stroke Risk in Women
A large-scale study suggests that people who have given birth and experience migraines while also smoking face a significantly higher risk of stroke before age 60.
🔬ResearchCBD Oil Found Ineffective for Managing Behavioral Issues in Youths with Intellectual Disabilities
A double-blind clinical trial published in JAMA Pediatrics indicates that CBD oil provides no significant behavioral improvement for children and teenagers with intellect…
🏃FitnessExpert Advice on Hydration Gear Sparks Debate Among Recreational Runners
Olympic medalist Josh Kerr recently suggested that runners may not require hydration packs for distances under 12 miles, igniting a broader conversation about gear necess…